Readmission Due to Infection Following Total Hip and Total Knee Procedures

Abstract

used to estimate the persistence of treatment overall and comparatively between biologics naïve patients and switchers from other biologics. Results: Threehundred-one (103 RA, 122 AS, 76 PsA) patients were followed for 515 patient-years (median 1.24 (IQR 0.5-2.7) years). The proportions of females in RA/AS/PsA groups were 76%/37%/51%. Median ages at golimumab initiation and times from diagnosis to golimumab treatment in RA/AS/PsA groups were 59/49/44 and 6.8/4.8/8.0 years, respectively. Golimumab was the first biologic in 79%/67%/70% of patients with RA/AS/PsA. Amongst RA patients 73%/74% were RF/ACPA positive and 86% of AS patients HLA-B27 positive. The proportions of RA/PsA patients who were on concomitant conventional DMARDs (glucocorticoids) at baseline were 85% (36%)/72% (8%). At the initiation of golimumab mean PromisHAQ was 40/31/39 in RA/AS/PsA; mean DAS28 5.6/5.0 in RA/PsA; mean BASDAI 5.9 in AS group(s). Among patients with measured disease activity at 6 (12) months 47% (59%)/77% (64%) of RA/PsA patients achieved DAS28< 3.2 and 54% (54%) of AS patients achieved at least 2.0 reduction of BASDAI. The proportions of RA/AS/PsA patients discontinuing golimumab treatment overall were 42%/23%/37%. Reasons for discontinuation were ineffectiveness in 68%/89%/71% in RA/AS/PsA. The unadjusted persistence of golimumab treatment for RA/AS/PsA at 6, 12, 24 months was 97%, 82%, 65%/96%, 91%, 73%/97%, 83%, 57%, respectively and did not differ significantly between biologics-naïve patients and switchers. ConClusions: In Slovenia, the persistence of golimumab after 2 years of treatment was 65%/73%/57% in RA/AS/PsA groups. Switcher status seems not to affect the persistence of golimumab regardless of indication.